Photonpharma Funding & Investors

Photonpharma develops an autologous cell therapy platform for the treatment of solid tumor cancers. Its technology stimulates a patient’s own immune system to seek out and destroy their cancer cells. The company has a patent-protected process that inactivates the DNA/RNA of a patient’s own tumor cells while leaving the cells alive with all of the unique tumor-specific antigen targets (neoantigens) intact.